Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Daikichiro Kobayashi, hereinafter ?Meiji?) and Dong-A ST Co., Ltd. (Headquarters: Seoul, South Korea, Chairman and CEO: Daesik Eom, hereinafter ?Dong-A ST?) have entered into an exclusive license agreement with Intas Pharmaceuticals Ltd. (Headquarters: Ahmedabad, India, Vice Chairman: Binish Chudgar, hereinafter ?Intas?) regarding DMB-3115 (development code), a proposed biosimilar to ustekinumab.   Under the terms of the agreement, Intas has been granted exclusive license rights to commercialize DMB-3115 worldwide, excluding Japan, South Korea and certain Asian countries. Meiji and Dong-A ST will develop, manufacture and supply DMB-3115 to Intas and its worldwide affiliates. In consideration of the license granted to Intas, Meiji and Dong-A ST will receive an upfront payment and are also eligible to receive developmental and sales milestones as well as profit share payments from Intas.   Meiji and Dong-A Socio Holdings, a parent company of Dong-A ST, entered into a strategic collaboration partnership agreement on biosimilar programs in September, 2011, and are currently co-developing DMB-3115, which is a proposed biosimilar to ustekinumab, a recombinant monoclonal antibody for the treatment of autoimmune diseases such as plaque psoriasis, Crohn?s disease and ulcerative colitis. The Phase III multi-regional clinical trial of DMB-3115 is being conducted in patients with plaque psoriasis in Europe and the United States.   Intas is a leader in development and commercialization of biosimilar products. It achieved an industry-first by being the first Indian company to launch a biosimilar product in the EU. In collaboration with Dong-A and Intas, Meiji aims to deliver DMB-3115 promptly to patients suffering from psoriasis and inflammatory bowel diseases and contribute to improvements in medical care and public health.

1. About Dong-A ST

Dong-A is one of the leading pharmaceuticals in Korea. Dong-A has solidified its leading market position on the strength of in-house developed products such as Suganon tab. Evogliptin, the DPP-4 inhibitor for type 2 diabetes mellitus, Zydena tab. Udenafil, the fourth PDE5 inhibitor in the world for erectile dysfunction, Stillen tab. Eupatilin for herbal treatment of gastritis and Motilitone tab. Corydaline for functional dyspepsia. Furthermore, Dong-A offers branded generic drugs (anti-cancer, anti-TB, etc.), bio-pharmaceutical, IMD, APIs and OTC products ensuring full compliance with international quality standard. Currently Dong-A exports its products to more than 50 countries to leading pharmaceutical companies in Europe, Latin America and Asia. For more information, please visit http://en.donga-st.com.

2. About Intas

Intas Pharmaceuticals Ltd. is a leading vertically integrated pharmaceutical company based in Ahmedabad, India, having end-to-end capabilities of formulation development, manufacturing and marketing along with backward integration of APIs. Intas has more than 16,000 employees, sells products in more than 85 countries and has 14 manufacturing sites worldwide. The Intas group?s revenues amounted to USD 2.1 bn in FY 2020 and the compounded annual growth rate of Intas? revenues has exceeded 25% in the past 10 years. For more information, please visit https://www.intaspharma.com/.